Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Wagner NB, Lenders MM, Kühl K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer SH, Kimeswenger S, Oellinger A, Forschner A, Leiter U, Weide B, Gassenmaier M, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen VA, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Eigentler TK. Wagner NB, et al. Among authors: ebel c. J Immunother Cancer. 2021 May;9(5):e002350. doi: 10.1136/jitc-2021-002350. J Immunother Cancer. 2021. PMID: 33986126 Free PMC article.
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner NB, Lenders MM, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler TK, Flatz L. Wagner NB, et al. Among authors: ebel c. Eur J Cancer. 2024 Jan;196:113425. doi: 10.1016/j.ejca.2023.113425. Epub 2023 Nov 21. Eur J Cancer. 2024. PMID: 38039778 Free article.
Molecular recognition of Escherichia coli R1-type core lipooligosaccharide by DC-SIGN.
Nieto-Fabregat F, Marseglia A, Thépaut M, Kleman JP, Abbas M, Le Roy A, Ebel C, Maalej M, Simorre JP, Laguri C, Molinaro A, Silipo A, Fieschi F, Marchetti R. Nieto-Fabregat F, et al. Among authors: ebel c. iScience. 2024 Jan 4;27(2):108792. doi: 10.1016/j.isci.2024.108792. eCollection 2024 Feb 16. iScience. 2024. PMID: 38299112 Free PMC article.
CD4+ regulatory T cells lacking Helios and Eos.
Polak K, Marchal P, Taroni C, Ebel C, Kirstetter P, Kastner P, Chan S. Polak K, et al. Among authors: ebel c. Biochem Biophys Res Commun. 2023 Sep 24;674:83-89. doi: 10.1016/j.bbrc.2023.06.087. Epub 2023 Jun 28. Biochem Biophys Res Commun. 2023. PMID: 37413709 Free article.
Powerful Avidity with a Limited Valency for Virus-Attachment Blockers on DC-SIGN: Combining Chelation and Statistical Rebinding with Structural Plasticity of the Receptor.
Porkolab V, Lepšík M, Ordanini S, St John A, Le Roy A, Thépaut M, Paci E, Ebel C, Bernardi A, Fieschi F. Porkolab V, et al. Among authors: ebel c. ACS Cent Sci. 2023 Feb 20;9(4):709-718. doi: 10.1021/acscentsci.2c01136. eCollection 2023 Apr 26. ACS Cent Sci. 2023. PMID: 37122470 Free PMC article.
190 results